We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
1
CALL
Viking Therapeutics
VKTX
$4B
$47.6M 6.02%
1,220,800
+561,600
+85% +$18.1M
ABVX
2
CALL
Abivax
ABVX
$10.1B
$46.5M 5.88%
349,200
+249,200
+249% +$28.2M
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$136B
$34.6M 4.37%
+600,000
New +$34.5M
ABVX
4
PUT
Abivax
ABVX
$10.1B
$33.6M 4.25%
252,400
+152,400
+152% +$17.2M
UTHR icon
5
United Therapeutics
UTHR
$21.1B
$28.7M 3.63%
52,989
+25,686
+94% +$14.5M
RVMD icon
6
Revolution Medicines
RVMD
$44.8B
$26.1M 3.29%
139,218
+58,346
+72% +$8.52M
ABVX
7
Abivax
ABVX
$10.1B
$21.6M 2.73%
163,644
+87,700
+115% +$9.93M
COGT icon
8
Cogent Biosciences
COGT
$6B
$19.1M 2.41%
493,664
+170,900
+53% +$5.98M
BMY icon
9
PUT
Bristol-Myers Squibb
BMY
$136B
$19M 2.41%
+330,600
New +$19M
CORT icon
10
CALL
Corcept Therapeutics
CORT
$11.9B
$17.9M 2.27%
206,300
+47,800
+30% +$2.89M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.9B
$17.9M 2.26%
312,846
+164,617
+111% +$9.02M
VKTX icon
12
Viking Therapeutics
VKTX
$4B
$17.2M 2.18%
441,808
-83,373
-16% -$2.69M
KYMR icon
13
CALL
Kymera Therapeutics
KYMR
$9.73B
$17.2M 2.17%
+149,700
New +$12.9M
NVS icon
14
PUT
Novartis
NVS
$304B
$15.7M 1.98%
+100,000
New +$15M
QURE icon
15
PUT
uniQure
QURE
$3.08B
$13.8M 1.74%
299,000
– –
VKTX icon
16
PUT
Viking Therapeutics
VKTX
$4B
$13.7M 1.73%
+350,500
New +$11.3M
BIIB icon
17
CALL
Biogen
BIIB
$32.7B
$13M 1.64%
+60,000
New +$11.5M
CAPR icon
18
PUT
Capricor Therapeutics
CAPR
$552M
$12.9M 1.63%
534,400
-89,000
-14% -$2.7M
SMMT icon
19
CALL
Summit Therapeutics
SMMT
$13.9B
$12.5M 1.58%
+860,200
New +$15.3M
LLY icon
20
PUT
Eli Lilly
LLY
$1.02T
$12M 1.52%
+10,000
New +$10.2M
INCY icon
21
PUT
Incyte
INCY
$25.9B
$11.9M 1.51%
105,400
– –
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.6B
$11.1M 1.4%
+272,214
New +$9.38M
QURE icon
23
CALL
uniQure
QURE
$3.08B
$10.8M 1.37%
235,400
-14,600
-6% -$382K
BNTX icon
24
CALL
BioNTech
BNTX
$26.2B
$9.3M 1.18%
+100,000
New +$9.41M
KOD icon
25
Kodiak Sciences
KOD
$2.22B
$8.5M 1.07%
218,117
+25,155
+13% +$979K
1
2 3 4 5

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.